Compare NAMS & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAMS | APGE |
|---|---|---|
| Founded | 2019 | 2022 |
| Country | Netherlands | United States |
| Employees | 100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | NAMS | APGE |
|---|---|---|
| Price | $34.72 | $132.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $46.75 | ★ $109.67 |
| AVG Volume (30 Days) | 1.1M | ★ 5.0M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $540.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.53 | $34.34 |
| 52 Week High | $42.21 | $133.16 |
| Indicator | NAMS | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 81.38 |
| Support Level | $33.83 | $73.70 |
| Resistance Level | $37.27 | $133.16 |
| Average True Range (ATR) | 1.53 | 1.68 |
| MACD | 0.56 | 2.74 |
| Stochastic Oscillator | 76.74 | 98.03 |
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.